Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Alterity Therapeutics AAN Presentation 5 May 2019

May 6, 2019August 16, 2022 Alterity Therapeutics

Alterity Therapeutics AAN Presentation 5 May 2019 Download

2019

Post navigation

Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting

Alterity Therapeutics commences US investor meetings following positive clinical data

Related Posts

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease

January 28, 2022August 16, 2022

ATH434 protects brain cells and improves motor function

April 21, 2021August 16, 2022

European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

June 23, 2021August 16, 2022

Recent Posts

Chairman’s Address 2024 Annual General Meeting
AGM 2024 Presentation
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065